CN100389773C - 新的能结合幽门螺杆菌的物质及其用途 - Google Patents

新的能结合幽门螺杆菌的物质及其用途 Download PDF

Info

Publication number
CN100389773C
CN100389773C CNB008172927A CN00817292A CN100389773C CN 100389773 C CN100389773 C CN 100389773C CN B008172927 A CNB008172927 A CN B008172927A CN 00817292 A CN00817292 A CN 00817292A CN 100389773 C CN100389773 C CN 100389773C
Authority
CN
China
Prior art keywords
helicobacter pylori
conjunction
purposes
acyl sphingosine
glycosphingolipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008172927A
Other languages
English (en)
Chinese (zh)
Other versions
CN1411376A (zh
Inventor
卡尔-安德斯·卡尔森
艾琳·伦纳德森
苏珊·特尼伯格
乔纳斯·安格斯特罗姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A+ Science AB
Original Assignee
A+ Science Invest AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A+ Science Invest AB filed Critical A+ Science Invest AB
Publication of CN1411376A publication Critical patent/CN1411376A/zh
Application granted granted Critical
Publication of CN100389773C publication Critical patent/CN100389773C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNB008172927A 1999-12-15 2000-12-15 新的能结合幽门螺杆菌的物质及其用途 Expired - Fee Related CN100389773C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904581A SE9904581D0 (sv) 1999-12-15 1999-12-15 A novel helicobacter pylori-binding substance and use thereof
SE99045817 1999-12-15

Publications (2)

Publication Number Publication Date
CN1411376A CN1411376A (zh) 2003-04-16
CN100389773C true CN100389773C (zh) 2008-05-28

Family

ID=20418126

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008172927A Expired - Fee Related CN100389773C (zh) 1999-12-15 2000-12-15 新的能结合幽门螺杆菌的物质及其用途

Country Status (18)

Country Link
US (1) US20040086514A1 (cg-RX-API-DMAC7.html)
EP (1) EP1237558A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003517015A (cg-RX-API-DMAC7.html)
CN (1) CN100389773C (cg-RX-API-DMAC7.html)
AU (1) AU783876B2 (cg-RX-API-DMAC7.html)
CA (1) CA2392766A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20021989A3 (cg-RX-API-DMAC7.html)
EE (1) EE200200312A (cg-RX-API-DMAC7.html)
HU (1) HUP0204243A3 (cg-RX-API-DMAC7.html)
IL (1) IL150247A0 (cg-RX-API-DMAC7.html)
NO (1) NO20022890L (cg-RX-API-DMAC7.html)
NZ (1) NZ520111A (cg-RX-API-DMAC7.html)
PL (1) PL356329A1 (cg-RX-API-DMAC7.html)
RU (1) RU2283115C2 (cg-RX-API-DMAC7.html)
SE (1) SE9904581D0 (cg-RX-API-DMAC7.html)
SK (1) SK8152002A3 (cg-RX-API-DMAC7.html)
WO (1) WO2001043751A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204251B (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
FI20010118L (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
EP1411952B1 (en) * 2001-06-29 2009-04-22 Glykos Finland Oy Use of at least one glycoinhibitor substance against infectious diseases
FI20011403L (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
AU2003201619A1 (en) * 2002-01-18 2003-07-30 Biotie Therapies Corporation Novel binding epitopes for helicobacter pylori and use thereof
EP1332759B1 (en) * 2002-02-04 2005-09-28 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical and nutritional compositions containing a di- or oligosaccharide as insulin secretion promoter
EP2272522B1 (en) * 2002-06-28 2017-09-06 Nestec S.A. Therapeutic compositions for use in prophylaxis or treatment of diarrheas
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
EP1866071A4 (en) * 2005-03-03 2013-04-24 Univ Indiana Res & Tech Corp PERMETHYLATION OF OLIGOSACCHARIDES
JP4677525B2 (ja) * 2005-08-23 2011-04-27 国立大学法人 長崎大学 ヘリコバクター・ピロリの空胞化毒素の検出試薬および検出方法
FR2906808B1 (fr) * 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
JP5014018B2 (ja) * 2006-10-18 2012-08-29 旭化成ケミカルズ株式会社 ピロリ菌の抑制剤または静菌剤
EP2098238B1 (en) * 2007-01-12 2012-10-17 The Noguchi Institute Helicobacter pylori growth inhibitor containing a monosaccharide derivative having an n-acetylglucosaminyl-group linked at the alpha position
EP2060257A1 (en) 2007-11-08 2009-05-20 Nestec S.A. Prevention and treatment of secondary infections following viral infection
GB0817908D0 (en) * 2008-10-01 2008-11-05 Univ Ghent Blood group a/b/h determinant on type 1 core glycosphinglipids chain as recognition point for the fedf protein of f18-fimbriated enterotoxigenic
JP5383692B2 (ja) 2008-10-10 2014-01-08 公益財団法人野口研究所 ピロリ菌増殖抑制剤
EP2844301A2 (en) * 2012-05-04 2015-03-11 Ineb-instituto de Engenharia Biomédica Microspheres for treating helicobacter pylori infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981003175A1 (en) * 1980-05-09 1981-11-12 H Leffler Carbohydrate derivatives for inhibiting bacterial adherence
EP0133170A2 (en) * 1983-07-15 1985-02-13 Ab Symbicom A compound and a composition for therapeutic or diagnostic use and a method for therapeutic treatment
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4678747A (en) * 1983-02-18 1987-07-07 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies for detection of an H (O) blood group antigen
DK17885D0 (da) * 1985-01-14 1985-01-14 Karlsson Karl Anders Antiviralt middel
US4971905A (en) * 1987-08-11 1990-11-20 Pacific Northwest Research Foundation Diagnosis of cancerous or precancerous conditions in human secretory epithelia by enzyme activity of β-1-3N-acetylglucosaminyltransferase
US4895838A (en) * 1988-03-09 1990-01-23 Trustees Of Boston University Method for provoking angiogenesis by administration of angiogenically active oligosaccharides
US4957741A (en) * 1988-08-02 1990-09-18 Angio-Medical Corp. Method for the treatment of gastric ulcer
US5877028A (en) * 1991-05-29 1999-03-02 Smithkline Diagnostics, Inc. Immunochromatographic assay device
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US6406894B1 (en) * 1992-12-11 2002-06-18 Glycorex Ab Process for preparing polyvalent and physiologically degradable carbohydrate-containing polymers by enzymatic glycosylation reactions and the use thereof for preparing carbohydrate building blocks
EP0601417A3 (de) * 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung
US6300113B1 (en) * 1995-11-21 2001-10-09 New England Biolabs Inc. Isolation and composition of novel glycosidases
DE4408248A1 (de) * 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
US5679769A (en) * 1994-03-15 1997-10-21 Sloan-Kettering Institute For Cancer Research Synthesis of asparagine-linked glycopeptides on a polymeric solid support
WO1995029927A2 (en) * 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
PL325873A1 (en) * 1995-09-29 1998-08-17 Glycim Oy Synthetic multivalent polysaccharide slex containing polylactose amines and methods of obtaining same
DE69737496D1 (de) * 1996-01-30 2007-05-03 Glycomimetics Inc SIALYL-LEWISa UND SIALYL LEWISx EPITOP-ANALOGE
US6841543B1 (en) * 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6709656B1 (en) * 1996-06-10 2004-03-23 Thomas Boren Helicobacter pylori adhesin binding group antigen
EP0926154B1 (en) * 1996-07-23 2010-01-27 Seikagaku Corporation Novel lactosamine oligosaccharides and process for the preparation thereof
US6902903B1 (en) * 1996-12-19 2005-06-07 Chiron Corporation Helicobacter pylori diagnostics
CN1281355A (zh) * 1997-12-12 2001-01-24 三阳株式会社 用于基因递送的生物可降解性混合聚合胶束
US6410057B1 (en) * 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
JP4318765B2 (ja) * 1998-04-01 2009-08-26 雪印乳業株式会社 ピロリ菌感染防御剤
KR100460173B1 (ko) * 1998-12-11 2004-12-04 겐 코오포레이션 헬리코박터 파일로리 정착 억제제
US20010051349A1 (en) * 2000-02-17 2001-12-13 Glycominds Ltd. Combinatorial complex carbohydrate libraries and methods for the manufacture and uses thereof
US20030100508A1 (en) * 1999-02-24 2003-05-29 Maryline Simon Carbohydrate epitope mimic compounds and uses thereof
WO2000070060A1 (en) * 1999-05-18 2000-11-23 University Of Iowa Research Foundation Production of complex carbohydrates
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
FI19992070A7 (fi) * 1999-09-28 2001-03-29 Carbion Oy Uudet fukosyloidut oligosakkaridit ja menetelmä niiden valmistamiseksi
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
FI20010118L (fi) * 2001-01-19 2002-07-20 Carbion Oy Uudet helicobacter pylori reseptorit ja niiden käyttö
EP1417965A1 (en) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
ES2344114T3 (es) * 2004-05-11 2010-08-18 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Lipooligosacaridos de neisseria meningitidis igtb como adyuvante.
EP1787128A2 (en) * 2004-07-09 2007-05-23 Amaox, Inc. Immune cell biosensors and methods of using same
US8273357B2 (en) * 2004-07-16 2012-09-25 Massachusetts Institute Of Technology Antigen-carbohydrate conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981003175A1 (en) * 1980-05-09 1981-11-12 H Leffler Carbohydrate derivatives for inhibiting bacterial adherence
EP0133170A2 (en) * 1983-07-15 1985-02-13 Ab Symbicom A compound and a composition for therapeutic or diagnostic use and a method for therapeutic treatment
JPH1045602A (ja) * 1996-07-31 1998-02-17 Motoyasu Murakami ヘリコバクター・ピロリ接着阻害剤またはインターロイキン−８産生阻害剤

Also Published As

Publication number Publication date
HUP0204243A3 (en) 2003-08-28
US20040086514A1 (en) 2004-05-06
ZA200204251B (en) 2003-05-28
NO20022890L (no) 2002-08-15
CN1411376A (zh) 2003-04-16
AU2418801A (en) 2001-06-25
SE9904581D0 (sv) 1999-12-15
SK8152002A3 (en) 2002-11-06
NO20022890D0 (no) 2002-06-17
NZ520111A (en) 2004-08-27
CZ20021989A3 (cs) 2002-10-16
WO2001043751A1 (en) 2001-06-21
EP1237558A1 (en) 2002-09-11
RU2283115C2 (ru) 2006-09-10
CA2392766A1 (en) 2001-06-21
AU783876B2 (en) 2005-12-15
HUP0204243A2 (hu) 2003-03-28
EE200200312A (et) 2003-06-16
JP2003517015A (ja) 2003-05-20
RU2002118703A (ru) 2004-02-20
PL356329A1 (en) 2004-06-28
IL150247A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
EP2272522B1 (en) Therapeutic compositions for use in prophylaxis or treatment of diarrheas
AU783876B2 (en) Novel helicobacter pylori-binding substances and use thereof
AU2002229792B2 (en) Novel receptors for Helicobacter pylori and use thereof
JP2005504017A (ja) 少なくとも１種の糖含有阻害性物質の用途
US20060122148A1 (en) High affinity receptors for helicobacter pylori and use thereof
AU2002229792A1 (en) Novel receptors for Helicobacter pylori and use thereof
US20050220819A1 (en) Novel binding epitopes for helicobacter pylori and use thereof
Hugosson et al. Glycosphingolipid binding specificities of Neisseria meningitidis and Haemophilus influenzae: detection, isolation, and characterization of a binding-active glycosphingolipid from human oropharyngeal epithelium
Miller-Podraza et al. Studies on gangliosides with affinity for Helicobacter pylori: binding to natural and chemically modified structures
WO2004065400A1 (en) Novel binding epitopes for helicobacter pylori and use thereof
Miller-Podraza et al. chemically modified structures

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080528

Termination date: 20111215